May 2008 Company Presentation UK. - Confidential - 2 FlowMedic’s goal is to be a global market leader providers of innovative, non-invasive medical devices.

May 2008

Company PresentationUK

- Confidential -2

FlowMedic’s goal is to be a global market leader providers of innovative, non-invasive medical devices for prevention and treatment of venous and arterial circulatory disorders in the extremities for both the medical and the OTC consumer markets

Mission Statement

- Confidential -3

Flowmedic Structure

Established in 2003

Privately owned by IBV private equity investment group

Fully owned subsidiaries in Israel (R&D) and the US (sales & marketing)

Outsourced manufacturing firmly established in China

- Confidential -4

Core Technology and Applications

Core Technology

Professional / Hospital

Home / Managed Care

Outpatient Clinics

OTC / Consumer

Post Op DVT Prophylaxis

Pre Op DVT Prophylaxis

Ven

us U

lcer H

ealingD

VT

T

reat

men

t

PAD

Intermittent Claudication

Neu

rop

athy

DV

T

Pro

ph

ylax

is

Improved Circulation

Edema reduction

Blo

od

S

timu

lation

DV

T

Pro

ph

ylax

is

PAD

CLI

Neu

rop

athyW

ou

nd

H

ealin

g

- Confidential -5

FlowMedic Scope of Products & Indications

Venous Indications DVT Prophylaxis (ortho, trauma, bariatric, stroke)

DVT Treatment

Arterial Indications Peripheral Arterial Disease (PAD) Intermittent Claudication (IC) Critical Limb Ischemia (CLI)

Diabetic Indications Extremities Ulcers Wound Healing (WH) Neuropathy (N)

Health & Wellness (OTC) DVT Prevention Blood Stimulation Edema Reduction

Actual Future

Peripheral Arterial Disease

- Confidential -6

Market Opportunity

FlowMedic products are geared towards a population of 20-30 million European and double that number worldwide affected by crippling and costly venous/ arterial and correlated disease indications, representing cumulative addressable markets of over $3.0 billion in revenues

- Confidential -7

Arterial Disease Implications

Peripheral Arterial Disease (PAD) affects 12 million U.S. citizens and approximately 30 million people worldwide (F&S and Datamonitor 2004)

Approximately 20% of the population over 70 and 30% of all diabetics are thought to have PAD (Clinical Cardiology Review, 2002)

Close to one million Americans are diagnosed for leg pain caused by poor vascular circulation, called Intermittent Claudication (ADA Consensus Statement)

Critical Limb Ischemia (CLI), a PAD related condition, affects 750,000 individuals in the United States, primarily diabetics

Every year, over 150,000 lower limb amputations are performed in the U.S. due to severe PAD and CLI

Leg ulcers affect as many as 2.5 million people in the U.S. causing substantial pain and loss of function

Severity Stage

PAD Prevalence Data

Higher Prevalence and Mortality than Many Leading Diseases

- Confidential -9

Flowmedic Unique Elastic Recoil™ Physiological Effect

Improved circulation in arteries that may be stiff due to diabetes, atherosclerosis, or other circulatory problems without causing user discomfort and associated low compliance– a major drawback of Intermittent Pneumatic Compression (IPC) devices

Increases arterial-venous pressure differences (by enhancing venous return) through mechanical compression

Improves pain-free walking distance

Improve quality of life

- Confidential -10

FM220TM Arterial Circulation System

FeaturesPortableEasily operated by patientsData logger for patient follow-upLight weightBattery operatedImproved hemodynamic performance at lowerlower peak pressure

StatusFDA 510K clearance and CE certifiedHCPCS code attained for arterial compression therapyCompleted clinical trials in PAD and Claudicant subjects Ongoing multi center clinical trial in USCommercially launched in the EU

Cleared b

y the

FDA & C

E mark

Improved Patient Compliance

- Confidential -11

The OTC opportunity - Some Statistic Numbers….

SOURCE: Reuters Business Insight; Internet sources, National Heart, Lung and Blood Institute; Scurr JH,(2001) Lancet, 357, 1485–1489; Jacobson BF, S Afr Med J. 2003 Jul;93(7):522-8; Hughes RJ,Lancet. 2003 Dec 20;362(9401):2039-44.

Over 250 million people with high income aged 50-80 living in Western countries

More than 500 million people fly > 4 hours flights annually

Clinical studies show that 1- 10% of fliers develop DVT

In the US, there are more than 18,750 air travel related DVT cases per month

30,000 world wide estimated flight related DVT deaths cases every year

- Confidential -12

Product Description

AviafitTM/HomefitTM is a light-weight, portable product that apply mechanical compression to stimulate circulation of blood in the legs while creating a pleasant, massage effect

AviafitTM/HomefitTM prevents blood stagnation, and reduces the risk of life-endangering blood cloth formation

- Confidential -13

AviafitTM/HomefitTM Pulsating Leg Band

FeaturesConvenient: very small footprint & lightweightWorn on both legs, over or under the clothingPortable, for use at home, office or travelSimple to usePleasant massage effect20 hours of continuous battery operation

StatusCompletion of in vitro verification, validation data and clinical data showing the positive effect of the product on flow parameters CE Mark receivedFDA clearance under 510K Class II classificationSuccessful launched in Europe throughpharmacy channels (> 1,000 PO’s)

Reusable StrapDevice Body

Device Panel

- Confidential -14

AviafitTM/HomefitTM Benefits

Improve wellbeing and quality of life

Effectively stimulates blood circulation in the legs, reducing

the risk of Deep Vein Thrombosis (DVT)

Effective results even while user is passive

Portable, battery-operated permits movement during use

Pleasant massage-like feeling

Applicable over or under the clothing – whatever is more

convenient

Excellent alternative to

elastic socks, medicine and foot massagers

- Confidential -15

Intellectual Property

54 filed and 19 granted / published patent applicationsPCT- WO 02/069879 – A portable device for the enhancement of circulation and for the prevention of stasis related deep vein thrombosis. Priority date: 5 March 2001 ( Published 12 Sep 2002)

24 new patent applications filed since (including also CIP applications and PCT applications)

National phase filed in USA, Japan, Canada, China, India, Australia, New Zealand, Brazil, Mexico, a regional phase in Europe and registration in Hong Kong

5 registered trademarks3 in Europe (CTM) and 2 in Japan

11 trademark applications: 3 in Europe (CTM), 6 in the U.S. and 2 in Israel

- Confidential -16

Company Management and Medical Advisory Board

Company ManagementProf. Shlomo Ben-Haim, MD - Co-Founder and ChairmanLewis C. Pell – Co-Founder and Director Dr. Benny Rousso - Co-Founder, Director and CTONissim Greisas – General Manager

Medical Advisory BoardProf. Daniel Burkhoff – Leading researcher in the cardiovascular field. Adjunct Associate Professor at Columbia University John Scurr, MD – Middlesex Hospital and University College Hospital, LondonRon Karmeli, MD - Chief of the Vascular Surgery Department, Carmel Hospital, Haifa, IsraelBenjamin Brenner, MD - Director of the Thrombosis and Homeostasis Unit and Deputy Director of the Department of Hematology at the Rambam Medical Center in Haifa, Israel